Oral atenolol therapy for proliferating infantile hemangioma A prospective study

摘要

Propranolol, a lipophilic nonselective beta-blocker, has recently been reported to be the treatment of choice for select types of infantile hemangiomas (IHs). Atenolol is a hydrophilic, selective beta(1)-blocker and therefore may be not associated with side effects attributable to beta(2)-adrenergic receptor blockade and lipophilicity. However, the efficacy and safety of atenolol in the treatment of IH are poorly understood. The aim of this study was to evaluate the efficacy and safety of atenolol in the treatment of proliferating IHs.